Publication Name	World Journal of Gastroenterology
Manuscript ID	39136
Country	France

Received	2018-03-29 03:58
Peer-Review Started	2018-03-29 09:15
To Make the First Decision	2018-04-27 02:04
Return for Revision	2018-04-27 06:36
Revised	2018-05-10 11:23
Second Decision	2018-05-17 09:00
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2018-05-18 01:41
Articles in Press	2018-05-18 01:41
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-05-22 08:57
Publish the Manuscript Online	2018-05-28 09:41

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Manuscript Source	Invited Manuscript
All Author List	Marc Hilmi, Laurent Bartholin and Cindy Neuzillet
ORCID	Author(s) ORCID Number Marc Hilmi http://orcid.org/0000-0003-4762-6740 Laurent Bartholin http://orcid.org/0000-0002-5637-3223 Cindy Neuzillet http://orcid.org/0000-0001-7037-7477
Funding Agency and Grant Number
Corresponding Author	Cindy Neuzillet, MD, MSc, Doctor, Doctor, Service d’Oncologie Médicale, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France. cindy.neuzillet@gmail.com
Key Words	Drug therapy combination; Immunology; Hypoxia; Checkpoint inhibitor; Inflammation; Pancreatic cancer; Tumor-infiltrating lymphocyte; Transforming growth factor; Tumor microenvironment
Core Tip	Checkpoint inhibitors (CPI) and other immune therapies remain inefficient when used as single agents in pancreatic ductal adenocarcinoma (PDAC). Here, we present an overview of the biological mechanisms underlying these failures and the lessons learned, giving a rationale for innovative combination therapies. In particular, the latest ongoing studies are attempting to overcome the immunosuppressive microenvironment, the basis of resistance to CPI in PDAC.
Publish Date	2018-05-28 09:41
Citation	Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? World J Gastroenterol 2018; 24(20): 2137-2151
URL	http://www.wjgnet.com/1007-9327/full/v24/i20/2137.htm
DOI	http://dx.doi.org/10.3748/wjg.v24.i20.2137

Full Article (PDF)	WJG-24-2137.pdf
Full Article (Word)	WJG-24-2137.doc
Manuscript File	39136-Review.docx
Answering Reviewers	39136-Answering reviewers.pdf
Audio Core Tip	39136-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	39136-Conflict-of-interest statement.pdf
Copyright License Agreement	39136-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	39136-Language certificate.pdf
Peer-review Report	39136-Peer-review(s).pdf
Scientific Misconduct Check	39136-Scientific misconduct check.pdf
Scientific Editor Work List	39136-Scientific editor work list.pdf